R & D

The ecosystem delivering biopharmaceutical innovation has shifted

Where global pharma companies had previously discovered, developed and delivered new products from their own labs, now the driving source of innovation is coming from smaller biotechnology and specialty pharma companies, as well as academia. 

Given this shift in innovation origination, Allergan has sought to follow a different R&D path than other companies.

We embrace an Open Science model


We Live Open Science
A Different R&D Path that Defines the Company’s Position
R&D Areas of Focus
Allergan is focused on researching and developing new therapies in our seven therapeutic areas.
Pre-Approval Access
Allergan Pre-Approval Access Program
Clinical Trials
Allergan Clinical Trials
Key Pipeline Programs
Allergan has more than a dozen key programs in development that derive from our Open Science pipeline.
Our Pipeline
Allergan has an Open Science pipeline powered by 60+ programs in development.